A new wave of biotech innovation powered by artificial intelligence is drawing global attention after researchers reported early-stage success in developing what they describe as a “fundamentally new” type of vaccine designed to protect against broad families of viruses.
Scientists at the University of Cambridge say artificial intelligence was used to design a key vaccine component from scratch, marking what they describe as the first instance of an AI-generated antigen being tested in human trials.
The development is being closely watched by the pharmaceutical and biotech industry because of its potential to disrupt traditional vaccine design, which typically relies on matching specific circulating virus strains.
Instead of targeting a single variant, the experimental vaccine is designed to train the immune system to recognise a shared structure across an entire virus family—particularly coronaviruses, including multiple Covid-19 variants and related animal viruses that could trigger future outbreaks.
Researchers believe this “broad-spectrum” approach could eventually reduce the need for frequent vaccine updates, a recurring cost and supply chain challenge for global health systems and vaccine manufacturers.
The project, led by scientists including Professor Jonathan Heeney of the University of Cambridge, used genetic data from multiple known coronaviruses collected through global surveillance programmes. An AI system analysed these viral sequences and designed a synthetic “super-antigen” intended to trigger immune responses across a wide range of related viruses.
In early clinical testing involving 39 volunteers, the vaccine was primarily assessed for safety. A larger follow-up trial involving about 200 participants is now underway to evaluate immune response strength and durability.
While early results suggest only a “modest” immune response, published findings in the Journal of Infection indicate the approach is scientifically promising and could be refined for stronger efficacy.
Experts involved in the trials, including Professor Saul Faust of the University of Southampton, say the AI-driven design approach shows strong long-term commercial and scientific potential, even if it remains in early development stages.
If successful at scale, the technology could reshape the global vaccine pipeline by enabling faster design cycles, reducing reliance on strain-by-strain updates, and opening a new frontier in pandemic preparedness investment.
